Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 5/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | PLK1 | P53350 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | INSR | P06213 | 1/20 | 0.46 |
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2062143 | 0.95 | SIRT6 (0.77) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL2820845 | 0.93 | SIRT6 (0.70) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL23534178 | 0.92 | SIRT6 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL29709935 | 0.92 | SIRT6 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL520231 | 0.91 | ALDH1A1 (0.76) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL311491 | 0.89 | ALDH1A1 (0.74) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL3722026 | 0.88 | ALDH1A1 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL311063 | 0.88 | ALDH1A1 (0.65) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL26043874 | 0.88 | ALDH1A1 (0.72) | SIRT6ALDH1A1LMNAMAPTHTR6 | |
| SCHEMBL517566 | 0.88 | ALDH1A1 (0.61) | SIRT6ALDH1A1LMNAMAPTHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111138492-B | Preparation method of ALK inhibitor brigatinib | 沈阳药科大学 | 2022-08-02 | — | — | CN | claimed |
| CN-111138492-A | Preparation method of ALK inhibitor brigatinib | 沈阳药科大学 | 2020-05-12 | — | — | CN | claimed |
| CN-119735613-A | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2025-04-01 | — | — | CN | disclosed |
| EP-2300013-B2 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-13 | — | — | EP | disclosed |
| EP-4393930-A1 | CRYSTAL FORMS, PREPARATION METHOD AND APPLICATION OF ARYL PHOSPHINE OXIDE COMPOUND | Chengdu Di'Ao Jiuhong Pharmaceutical Factory (CN) | 2024-07-03 | — | — | EP | disclosed |
| CN-118221696-A | Pyrimidine heterocyclic compound containing N-methylpiperazine structure, and preparation method and application thereof | 潍坊医学院 | 2024-06-21 | — | — | CN | disclosed |
| CN-114829352-B | Novel deuterated pyrimidine derivative and pharmaceutical composition containing same | 昂科比克斯有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2024-02-15 | — | — | US | disclosed |
| US-20240043457-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4[(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-08 | — | — | US | disclosed |
| CN-111888368-B | Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine | 武田药品工业株式会社 | 2024-02-02 | — | — | CN | disclosed |
| WO-2024017258-A1 | EGFR SMALL MOLECULE INHIBITOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 百极弘烨(南通)医药科技有限公司 | 2024-01-25 | — | — | WO | disclosed |
| WO-2010138578-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010138575-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143389-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2008-06-05 | — | — | US | disclosed |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | NOVARTIS AG (CH) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240051940-A1 | SULFONAMIDES WITH EGFR INHIBITION ACTIVITIES AND THEIR USE THEREOF | EGFR, ERBB2, ERBB4 | SIRT6 2667/4885ALDH1A1 3574/4885LMNA 4763/4885 |
| US-20080132504-A1 | 2, 4-Pyrimidinediamines Useful In The Treatment Of Neoplastic Diseases, Inflammatory And Immune System Disorders | TYMS, TYMP, DPYD | SIRT6 2197/4885ALDH1A1 647/4885LMNA 3066/4885 |
| US-20240043457-A1 | CRYSTALLINE FORMS OF 5-CHLORO-N4-[-2-(DIMETHYLPHOSPHORYL) PHENYL]-N2-{2-METHOXY-4-[4[(4-METHYLPIPERAZIN-1-YL) PIPERIDIN-1-YL] PHENYL} PYRIMIDINE-2,4-DIAMINE | ERBB2, ERBB4, CDK2 | SIRT6 2730/4885ALDH1A1 4265/4885LMNA 2711/4885 |
| US-20060247241-A1 | 2,4-Di (phenylamino) pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders | TYMS, UMPS, TYMP | SIRT6 2258/4885ALDH1A1 583/4885LMNA 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.